A new therapeutic approach for the treatment of sepsis

Abstract 

Despite important advances in understanding its pathophysiology, therapy for septic shock remains largely symptomatic and supportive. Aiming to elevate the systemic arterial blood pressure by using vasoconstrictor manoeuvers are preferred without paying much attention to the ischaemia produced at the peripheral tissues. Since, these maneuvers proved no remarkable success in reducing the mortality up to date, we now propose a different perspective in this manuscript. Although it is not always easy to distinguish the different phases of septic shock, at least two fundamentally different phases can be distinguished, i.e. (i) hyperdynamic phase and (ii) hypodynamic phase mandating the adoption of vasodilative and vasoconstrictive interventions, consequently. Additionally, endothelium-derived vasodilator and vasoconstrictor substances such as nitric oxide and endothelin play key roles in systemic inflammatory response syndrome that lead to fatal multiple organ dysfunction. Therefore, we hypothesize that the inhibition of nitric oxide production during earlier phases of septic shock combined with the blockade of endothelin receptors at later stages appear feasible and a novel strategy for the therapy of septic shock.